methyl 4-<(tert-butyloxycarbonyl)amino>-5-(O-tosyl)pentanoate | 130223-39-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 4-<(tert-butyloxycarbonyl)amino>-5-(O-tosyl)pentanoate
• 英文别名: methyl (S)-4-((tert-butoxycarbonyl)amino)-5-(tosyloxy)pentanoate；methyl (4S)-4-[(tert-butoxy)carbonylamino]-5-[(4-methylphenyl)sulfonyloxy]pentanoate；Methyl(4S)-4-[(tert-butoxy)carbonylamino]-5-[(4-methylphenyl)sulfonyloxy]pentanoate；methyl (4S)-5-(4-methylphenyl)sulfonyloxy-4-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
• CAS: 130223-39-1
• 化学式: C₁₈H₂₇NO₇S
• 分子量: 401.481
• InChiKey: NVVWJSURGDRQLC-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 4-<(tert-butyloxycarbonyl)amino>-5-(O-tosyl)pentanoate 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 4.0h， 生成 (S)-4-tert-butoxycarbonylamino-5-iodo-pentanoic acid methyl ester
  参考文献：
  名称：

  Synthesis of Enantiomerically Pure β- and γ-Amino Acids from Aspartic and Glutamic Acid Derivatives

  摘要：

  描述了一种高效合成手性纯的β-和γ-氨基酸的方法，该方法从市售的谷氨酸和天冬氨酸衍生物出发。首先将氨基酸的α位羧基转化为良好的离去基团，然后与有机铜试剂反应，生成β-和γ-氨基酸酯。经过脱保护步骤后，以良好的总产率获得β-和γ-氨基酸。

  DOI：

  10.1055/s-1992-26315
• 作为产物：
  描述：

  N-叔丁氧羰基-L-谷氨酸 5-甲酯 在 吡啶 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.5h， 生成 methyl 4-<(tert-butyloxycarbonyl)amino>-5-(O-tosyl)pentanoate
  参考文献：
  名称：

  Synthesis of Enantiomerically Pure β- and γ-Amino Acids from Aspartic and Glutamic Acid Derivatives

  摘要：

  描述了一种高效合成手性纯的β-和γ-氨基酸的方法，该方法从市售的谷氨酸和天冬氨酸衍生物出发。首先将氨基酸的α位羧基转化为良好的离去基团，然后与有机铜试剂反应，生成β-和γ-氨基酸酯。经过脱保护步骤后，以良好的总产率获得β-和γ-氨基酸。

  DOI：

  10.1055/s-1992-26315

文献信息

• [EN] TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS MODULATEURS DE TLR2, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：AXIAL THERAPEUTICS INC

  公开号：WO2021242923A1

  公开（公告）日：2021-12-02

  The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

  本公开涉及调节Toll样受体（TLR）蛋白活性的化合物，包括激动剂或激活剂、部分激动剂和拮抗剂。特别感兴趣的是调节TLR2活性的化合物，以及使用这些化合物治疗与TLR2通路相关的癌症和其他疾病的方法。
• Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
  申请人：Albers J. Ronald

  公开号：US20060287344A1

  公开（公告）日：2006-12-21

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供的是具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，以及包含有效量氨基嘌呤化合物的组合物和用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合征、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Albers Ronald J.

  公开号：US20090275564A1

  公开（公告）日：2009-11-05

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量氨基嘌呤化合物的组合物，以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、与疾病相关的消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK途径治疗或预防的疾病的方法，包括向需要治疗的患者注射有效量的氨基嘌呤化合物。
• Methods of treatment and prevention using haloaryl substituted aminopurines
  申请人：Bennett L. Brydon

  公开号：US20080021048A1

  公开（公告）日：2008-01-24

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供了具有以下结构的氨基嘌呤化合物：其中R1、R2和R3的定义如本文所述，包含有效量的氨基嘌呤化合物的组合物以及用于治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或通过抑制JNK通路可治疗或预防的疾病的方法，包括向需要治疗的患者施用有效量的氨基嘌呤化合物。
• METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HALOARYL SUBSTITUTED AMINOPURINES OR COMPOSITIONS THEREOF
  申请人：Albers Ronald J.

  公开号：US20090312320A1

  公开（公告）日：2009-12-17

  Provided herein are Aminopurine Compounds having the following structure: wherein R 1 , R 2 and and R 3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

  本文提供具有以下结构的氨基嘌呤化合物：其中R1、R2和R3如下定义，包含有效量的氨基嘌呤化合物的组合物以及治疗或预防癌症、心血管疾病、肾脏疾病、自身免疫疾病、炎症性疾病、黄斑变性、缺血再灌注损伤、疼痛和相关综合症、疾病相关消耗、石棉相关疾病、肺动脉高压或可通过抑制JNK通路治疗或预防的疾病的方法，包括向需要的患者施用有效量的氨基嘌呤化合物。